Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
"Comprehensive reagent toolkit for SIK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIK2 Recombinant Protein (Active Domain / Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9 or E. coli expressed. |
View SIK2 Products |
| Gene Delivery | SIK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View SIK2 Products |
| Benchmark Ab | Anti-SIK2 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and IP. |
View SIK2 Products |
| Validator | SIK2 siRNA Set Target-specific knockdown verification in tumor or immune cells. |
View SIK2 Products |
| Related Target A | SIK1 Essential for subfamily selectivity profiling to avoid off-target toxicity. |
View SIK1 Products |
| Related Target B | SIK3 Evaluated alongside SIK2 in ovarian cancer mitosis and metabolic regulation. |
View SIK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIK Subfamily Selectivity (SIK1/2/3) | Human SIK1, SIK2, and SIK3 ortholog proteins available with >95% purity for robust cross-screening. |
| High-Throughput Kinase Profiling | Sequence-verified kinase domains with high batch-to-batch consistency and theoretical MW validation. |
| In Vivo & In Vitro Knockdown Controls | Validated siRNA sets and high-titer Lentiviral particles for stable cell line construction. |
| Lack of Assay Baseline Controls | Recombinant benchmark antibodies included to establish reliable assay thresholds. |
Live SIK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIK2 (Salt-Inducible Kinase 2) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum kinase inhibitors to highly selective small molecule inhibitors and SIK-targeted PROTACs (Proteolysis Targeting Chimeras). As first-generation pan-SIK inhibitors reach clinical and preclinical milestones, the next wave of R&D is targeting isoform-selective SIK2 inhibition to maximize therapeutic index in oncology (particularly ovarian and breast cancers) and autoimmune diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Galapagos, Merck, Academic Consortia | Ovarian Cancer, Autoimmune Diseases | Selectivity Assay (Need SIK1/2/3 Mutant & WT Proteins) |
| PROTAC / Degraders | Preclinical Biotechs | Triple-Negative Breast Cancer (TNBC) | Degradation Kinetics (Need Lentivirus for Stable Reporter Lines) |
| Combination Therapies | Clinical Investigators | Paclitaxel-Resistant Tumors | Synergy Validation (Need SIK2 siRNA for knockdown comparison) |